INS and obesity disorder: Given that FHL2 has been mechanistically associated with insulin secretion [24,26], diabetic kidney disease [25], and obesity [27], and that SNPs and epigenetic changes in FHL2 are associated with T2D [24] and body fat mass [28], we hypothesized that FHL2 genetic variants may also be associated with specific markers of glucose and lipid metabolism such as fasting plasma glucose values and plasma TG concentrations in humans.